DEPLOYDatabase

Robot model

ReWalk 7

exoskeletoncommercialby Lifeward

Powered lower-limb personal exoskeleton; latest ReWalk generation, FDA cleared March 2025.

Manufacturer
Lifeward
Form factor
exoskeleton
Maturity
commercial
Lifecycle
active
Deployments
1

The verified answer

As of Sep 2026, DEPLOY verifies ReWalk 7, a exoskeleton by Lifeward (commercial): 1 verified deployment on record. 2 sources back the record.

Regulatory status1 CE marking1 FDA 510(k) clearance

ReWalk 7 holds 1 CE marking and 1 FDA 510(k) clearance, per the DEPLOY registry.

See all 2 filings

Overview

Powered lower-limb personal exoskeleton; latest ReWalk generation, FDA cleared March 2025. Motor-driven powered gait for spinal-cord-injury users.

Verified vs. claimed

Maturity stage
commercial(Commercially deployed with revenue-generating operations.)
Sources on file
View all sources →

Key facts

Type

Exoskeleton for rehabilitation

Specs

Use

medical (personal, SCI)

Control

weight-shift triggered powered gait

Powered

yes (motor-driven)

Regulatory

FDA cleared 2025-03

Body region

lower-limb

Availability

commercial (2025 launch)

Data & sources

Press releases

1

Web sources

1

2 sources backing this record.View all →

Pricing

No verified price is on record for ReWalk 7. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.

Deployments (1)

  • ReWalk 7 (FDA cleared March 2025) is the latest generation personal exoskeleton for spinal-cord-injury users.

Free to use on your site, with a link back to DEPLOY.

ReWalk 7 on the deployment map

View the global map

Where ReWalk 7 is verified operating. Explore the deployment map by place and type.

Free to use on your site, with a link back to DEPLOY.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Deployment-verified media (1)

PRIMARY SOURCE
Courtesy of Lifeward

Lifeward's footage of a user navigating stairs and curbs in the current-generation ReWalk personal exoskeleton (ReWalk 7). Stepping is triggered by tilt sensors and the user's forward body-weight shift, with crutches for balance: worn and user-controlled, not autonomous.

From deployment: United States

Regulatory filings (2)

Safety record

1 recall and 1 incident on record (2 serious). Most recent: Dec 2019.

serious
2
injury
1
recall
1

Most recent: Dec 2019

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Incidents affecting ReWalk 7 (2)

Includes incidents linked directly to this model or to deployments of it. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Sources (2)

  1. https://ir.golifeward.com/news-releases/news-release-details/fda-issues-clearance-rewalk-7-exoskeleton
  2. https://golifeward.com/

Common questions

What is ReWalk 7?
Powered lower-limb personal exoskeleton; latest ReWalk generation, FDA cleared March 2025. Motor-driven powered gait for spinal-cord-injury users.
How much does ReWalk 7 cost?
ReWalk 7's price is not publicly disclosed. DEPLOY has no verified price on record for ReWalk 7 from Lifeward. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
Is ReWalk 7 actually deployed in the real world?
Yes. ReWalk 7 is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
Who makes ReWalk 7?
ReWalk 7 is made by Lifeward, based in Marlborough, MA, USA / Yokneam Ilit, Israel, founded in 2001.
Where is ReWalk 7 deployed?
1 verified deployment of ReWalk 7 is on the DEPLOY registry, including at United States.
Can you buy ReWalk 7?
ReWalk 7 is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
Is ReWalk 7 FDA cleared?
ReWalk 7 has 2 regulatory records on the DEPLOY registry: CE marking, cleared; FDA 510(k) clearance (K241822), cleared. See the Regulatory filings section for each agency source.
What are alternatives to ReWalk 7?
On the DEPLOY registry, comparable exoskeleton robots to ReWalk 7 include Ant-H1 Pro, Cyberdyne HAL, German Bionic Cray X, HANK.
How does ReWalk 7 compare to Ant-H1 Pro?
ReWalk 7 and Ant-H1 Pro (Kenqing Technology · 5 deployments) are both exoskeleton robots on the DEPLOY registry. ReWalk 7 has 1 verified deployment on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
Is ReWalk 7 a top exoskeleton?
On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, ReWalk 7 ranks in roughly the top 68% of exoskeleton models tracked by the registry.
What is ReWalk 7's maturity stage?
ReWalk 7 is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
Is ReWalk 7 safe?
ReWalk 7 has 2 active incidents on record in the DEPLOY registry. 1 recall and 1 incident on record (2 serious). Most recent: Dec 2019. Retracted incidents are excluded from this count.
How much does a ReWalk exoskeleton cost?
The ReWalk Personal Exoskeleton costs approximately $77,000 to $85,000 per unit. It is a wearable robotic exoskeleton that provides powered leg motion for people with spinal cord injury to stand and walk. ReWalk 7 is the latest generation, FDA-cleared under 510(k) K241822.
Methodology: Verified · 2 sources (1 primary) · last reviewed 2026-07-08

Verification posture

Verified

High confidence

Review state

Stable

Last reviewed 2026-07-08

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: active

Architectural position

Cohort: exoskeleton

Sources by quality tier

1
primary-company-ir
Company IR disclosure
1
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for ReWalk 7.

Recent coverage

ReWalk 7 in third-party press